Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Reimburse with clinical criteria and/or conditions | Complete | ||
Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete | ||
Viibryd | vilazodone | Depression, Major depressive disorder | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Victoza | liraglutide | Diabetes Mellitus, Type 2 (pediatric) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Victoza | Liraglutide | Diabetes Mellitus, Type 2 | Withdrawn | |||
Victoza | Liraglutide | Diabetes mellitus, Type 2 | Do not list | Complete | ||
Viberzi | eluxadoline | Irritable bowel syndrome with diarrhea | Do not reimburse | Complete |